Skip to main content
Fig. 2 | Stem Cell Research & Therapy

Fig. 2

From: Urokinase-type plasminogen activator receptor interaction with β1 integrin is required for platelet-derived growth factor-AB-induced human mesenchymal stem/stromal cell migration

Fig. 2

PDGF-AB regulates uPAR and uPA expression in BM-MSC. BM-MSC were grown in serum-free control medium or treated with PDGF-AB. a Quantitative PCR analysis of uPAR mRNA synthesis 5, 10, or 24 hours after treatment. Data from four donors are presented as the uPAR mRNA fold change relative to nonstimulated control cells for each donor (1 = no stimulation). b Flow cytometry analysis of uPAR cell surface expression; 24 hours after treatment, cells were stained with anti-uPAR monoclonal antibody (dark curves) or its isotypic control (grey curves). One representative experiment of one donor of the five assessed is shown (left). Quantification data (right) expressed as mean ± SEM of uPAR fluorescence intensity relative to the isotype of five independent experiments (one donor per experiment). *P <0.05. c Western blot analysis of uPAR in cellular membranes 24 hours after treatment.***P <0.001 d Quantitative PCR analysis of uPA mRNA synthesis 5, 10, or 24 hours after treatment. Data from four donors are presented as uPA mRNA fold change relative to nonstimulated control cells for each donor (1 = no stimulation). e Western blot analysis of uPA in cellular membranes 24 hours after treatment. f Zymographic analysis of uPA activity in cellular membranes 24 hours after treatment. Purified high molecular weight human urokinase was used as standard (ST). c, e, f (left) Data represent one representative experiment, (right) bands were quantified by densitometry analysis using ImageJ software, normalized to β-actin (c, e). Data expressed as mean ± SEM of three to five independent experiments (one donor per experiment). MFI mean fluorescence intensity, PDGF-AB platelet-derived growth factor AB, PE phycoerythrin, uPA urokinase-type plasminogen activator, uPAR urokinase-type plasminogen activator receptor

Back to article page